Navigation Links
Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
Date:11/7/2012

and expectations. These forward-looking statements include statements regarding the timing of enrollment and rate of MACE in the Light Study, the ability to gain agreement with FDA on the procedural details for a Contrave NDA resubmission in advance of the Light Study interim data, the timing of the subsequent resubmission of the NDA for Contrave, the timing of approval for Contrave, the submission of an application for marketing authorization in Europe and the negotiation of a partnership for the rest-of-world rights to Contrave and Empatic, the expected cash balance at the end of 2012, the expected cash usage for the year 2012, the development of Empatic and the communication with the FDA, the possibility that a cardiovascular outcomes trial will be needed for Empatic, and the commercial potential of Contrave and Empatic. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: Orexigen's ability to conduct the Light Study and the progress and timing thereof; Orexigen's ability to demonstrate in the Light Study that the risk of MACE in overweight and obese subjects treated with Contrave does not adversely affect the product candidate's benefit-risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study or Phase III trials for Empatic; the Special Protocol Assessment (SPA) is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; the potential for the FDA to not approve Contrave or Empatic; the potential for early termination of the collaboration agreement betwe
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
11. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... YORK , 21. Mai 2015 ... DPRX ), ein Unternehmen für ... auf die Entwicklung und Vermarktung von ... konzentriert, kündigte heute eine wissenschaftliche Posterpräsentation ... Phase-III-Zulassungsstudie des Unternehmens vorstellt, OneStep-1 und ...
(Date:5/21/2015)... CHICAGO , May 21, 2015  Heidrick & ... executive search , leadership consulting and ... life sciences expertise among global practices announcing the addition ... Chicago office. Dietlin ... has worked globally and across R&D, Medical and Commercial ...
(Date:5/21/2015)... , May 21, 2015  Today, eight ... who prescribe biologics – Alliance for Patient ... College of Rheumatology, Biologics Prescribers Collaborative, Clinical ... Endocrine Society, and North American Society for ... a letter to U.S. Food and Drug ...
Breaking Medicine Technology:Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7Heidrick Increases Healthcare and Life Sciences Expertise 2Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 2Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 3Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 4
... Jan. 14, 2011 New clinical research data suggests ... tools used by physicians and provide accurate identification of ... neurodegeneration linked to Alzheimer,s Disease (AD).  Flutemetamol, a GE ... phase III development, is being studied to identify the ...
... Baylor Health Care System is today announcing its intent ... in North Texas through the implementation of the electronic ... is one of thousands of hospitals and eligible professionals ... of Health and Human Services (HHS) to demonstrate its ...
Cached Medicine Technology:GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease 2GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease 3Baylor Health Care System Registers its Commitment to Achieve Meaningful Use of the Electronic Health Record 2
(Date:5/22/2015)... Wimbledon Health Partners, the leading on-site ... and NCV testing , is proud to announce ... American National athlete, to the Wimbledon Athletics division. ... level of testing and information it provides to be ... trainers, this way they can focus on the task ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Steven Winter ... Marc Zuluaga, has been selected by Consulting-Specifying Engineer (CSE) ... award winners are featured in the May/June issue of ... building industry professionals age 40 and younger who have, ... community, as well as in other areas of their ...
(Date:5/22/2015)... Calif. (PRWEB) May 22, 2015 Bryce ... opened Anaheim Fit Body Boot Camp, recently accepted his ... so quickly after the launch of his location evidences ... the Anaheim community. , Fit Body Boot Camp is ... boot camp franchise with hundreds of locations across North ...
(Date:5/22/2015)... May 22, 2015 Javon Bea ... be recognized for providing the highest quality emergency care ... health care decision-making,” said Javon R. Bea, President and ... commitment of our employee/partners to care for and respond ... Hospitals do not apply for this award, but are ...
(Date:5/21/2015)... Los Angeles, California (PRWEB) May 21, 2015 ... Angeles area at the Hilton Hotel in San Gabriel on ... heard over and over again from men and women who ... can find the right partner." , "Many singles think that ... right person. The seeker would go from one relationship to ...
Breaking Medicine News(10 mins):Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3Health News:Steven Winter Associates’ Marc Zuluaga Earns Innovative Engineering Award 2Health News:Healthy Living Brought to Anaheim— New Fitness Boot Camp Acquires 100 Clients 2Health News:Mercy Hospital and Trauma Center Receives Women’s Choice Award for Emergency Care - Mercy Health System Javon Bea 2Health News:Bestselling Author Sheds Light on Why Modern Dating is Hurting People's Chances of Finding a Lasting Relationship 2
... doesn,t prove it,s safe, critics say , , TUESDAY, April ... appears to slow the progression of atherosclerosis in diabetic ... them from new cardiac problems, according to the results ... been associated with increased risk of heart attack and ...
... reduction in Meth use, PALTO ALTO, Calif., ... its new advertising campaign, including a series of,television ... the Oscar-nominated director and producer whose works,include "Babel," ... launched,today in Montana, are designed to communicate the ...
... his April 1, 2008 show,Dr. Phil finally brought MRSA ... aureus) has been relatively unseen on,national TV. Dr. Phil ... an entire show to the problem. The program showcased ... had a son die as a result,of the deadly ...
... Ga., April 1, 2008 Immucor, Inc.,(Nasdaq: ... instrument-reagent,systems to the blood transfusion industry, today reported ... 29, 2008., Revenue for the fiscal third ... in the same period last year. Of the ...
... sixfold increase in positive portrayal of substance abuse over ... -- Rap music is glamorizing drug use, according to ... Berkeley, who found a sixfold increase in drug ... "Positive portrayals of drug use have increased over time, ...
... Fashion, Kid Sister, Emmanuel Jal & More Help Mobilize College Students ... ... mtvU ( http://www.mtvu.com/ ),MTV,s Emmy-winning college network, in partnership with ... a month of exclusive album leaks and video premieres on mtvU.com,and ...
Cached Medicine News:Health News:Avandia May Slow Atherosclerosis After Bypass Surgery 2Health News:Avandia May Slow Atherosclerosis After Bypass Surgery 3Health News:Oscar-Nominated Filmmaker Alejandro Gonzalez Inarritu Directs New Meth Project Advertising Campaign 2Health News:Oscar-Nominated Filmmaker Alejandro Gonzalez Inarritu Directs New Meth Project Advertising Campaign 3Health News:Oscar-Nominated Filmmaker Alejandro Gonzalez Inarritu Directs New Meth Project Advertising Campaign 4Health News:Daytime TV Addresses the Onslaught of MRSA Cases in U.S. 2Health News:Immucor Announces Record Fiscal Third Quarter Results 2Health News:Immucor Announces Record Fiscal Third Quarter Results 3Health News:Immucor Announces Record Fiscal Third Quarter Results 4Health News:Immucor Announces Record Fiscal Third Quarter Results 5Health News:Immucor Announces Record Fiscal Third Quarter Results 6Health News:Immucor Announces Record Fiscal Third Quarter Results 7Health News:Immucor Announces Record Fiscal Third Quarter Results 8Health News:Rap Music Glorifying Drug Use 2Health News:mtvU Unleashes Month OF Exclusive Album 'Leaks' & Music Video Premieres in Continued Fight Against Darfur Genocide 2Health News:mtvU Unleashes Month OF Exclusive Album 'Leaks' & Music Video Premieres in Continued Fight Against Darfur Genocide 3Health News:mtvU Unleashes Month OF Exclusive Album 'Leaks' & Music Video Premieres in Continued Fight Against Darfur Genocide 4Health News:mtvU Unleashes Month OF Exclusive Album 'Leaks' & Music Video Premieres in Continued Fight Against Darfur Genocide 5
... a compact Latex based reagent kit to detect ... to determine the level of RF semi-quantitatively in ... The kit includes antigen coated fine latex particles ... in plastic squeezable dropping bottles, re-usable plastic slide, ...
RFScan Latex Test Kit-100...
The Array 360 CEAL streamlines processes with computer enhancements and optimizes productivity by offering an exclusive design for aliquot samples....
ELISA kit for detection of Rheumatoid Factor....
Medicine Products: